French AFU Cancer Committee Guidelines-Update 2022-2024: prostate cancer-Diagnosis and management of localised disease

G Ploussard, G Fiard, E Barret, L Brureau… - Progrès en Urologie, 2022 - Elsevier
Objective The objective of the French Urology Association Cancer Committee is to propose
an update of the recommendations for the diagnosis and management of prostate cancer …

Radioactive iodine-125 in tumor therapy: advances and future directions

S Wei, C Li, M Li, Y Xiong, Y Jiang, H Sun, B Qiu… - Frontiers in …, 2021 - frontiersin.org
Radioactive iodine-125 (I-125) is the most widely used radioactive sealed source for
interstitial permanent brachytherapy (BT). BT has the exceptional ability to deliver extremely …

Recommandations françaises du Comité de cancérologie de l'AFU–actualisation 2020–2022: cancer de la prostate

F Rozet, P Mongiat-Artus, C Hennequin, JB Beauval… - Progrès en Urologie, 2020 - Elsevier
Objective.-The purpose of the guidelines national committee ccAFU was to propose updated
french guidelines for prostate cancer. Methods.-A Medline search was achieved between …

[HTML][HTML] A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer

F Slevin, F Zattoni, E Checcucci… - European Urology …, 2023 - Elsevier
Context The optimum use of brachytherapy (BT) combined with external beam radiotherapy
(EBRT) for localised/locally advanced prostate cancer (PCa) remains uncertain. Objective …

Prostate cancer brachytherapy: SFRO guidelines 2021

P Pommier, M Ferré, P Blanchard, É Martin… - Cancer …, 2022 - Elsevier
Prostate brachytherapy techniques are described, concerning both permanent seed implant
and high dose rate brachytherapy. The following guidelines are presented: brachytherapy …

A brief review of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy boost for high-risk prostate

BW Fischer-Valuck, HA Gay, S Patel… - Frontiers in …, 2019 - frontiersin.org
For patients with unfavorable or high-risk prostate cancer, dose escalated radiation therapy
leads to improved progression free survival but attempts to deliver increased dose by …

Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for …

MG Parry, J Nossiter, A Sujenthiran, TE Cowling… - International Journal of …, 2021 - Elsevier
Purpose External beam radiation therapy (EBRT) with brachytherapy boost reduces cancer
recurrence in patients with prostate cancer compared with EBRT monotherapy. However …

High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized …

H Yamazaki, K Masui, G Suzuki, N Aibe, D Shimizu… - Scientific Reports, 2021 - nature.com
To compare the outcomes of localized prostate cancer treatment with high-dose-rate
brachytherapy (HDR-BT) and low-dose-rate brachytherapy (LDR-BT), we examined 924 …

[HTML][HTML] A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in …

F Slevin, SL Rodda, P Bownes, L Murray… - Clinical and translational …, 2020 - Elsevier
Introduction There is evidence to support use of external beam radiotherapy (EBRT) in
combination with both low dose rate brachytherapy (LDR–EBRT) and high dose rate …

Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy

Y Imai, F Urabe, K Iwatani, M Nakazono… - International Journal of …, 2023 - Springer
Background Although brachytherapy is a standard treatment option for patients with high-
risk prostate cancer, only a few studies have compared low-dose-rate brachytherapy (LDR …